

# ANAEMIA NEUTROPENIA THROMBOSIS AND CANCER COURSE

16<sup>th</sup> Annual Course  
Vienna, Austria  
March 31<sup>st</sup> - April 1<sup>st</sup>, 2017

**Chairs:**

C. Bokemeyer, M. Dicato,  
P. Gascon, H. Ludwig

**Course co-ordinator:**

M. Aapro

The course has been approved  
to be announced as an  
ESO Recommended Event



Auspices of:



EACCME accreditation has granted 6 European CME credits (ECMEC)

## Friday, March 31<sup>st</sup>, 2017

- 10:00 Registrations Open
- 12:00-13:00 Buffet Lunch
- 13:00-13:10 **Welcome:** Chairmen and Coordinator
- 13:10-16:30 **SESSION 1: Anaemia in Cancer Patients**  
Chairman: *D. Schrijvers*
- 13:10-13:25 Pathophysiology, incidence and implications of anaemia in cancer patients  
*D. Schrijvers*
- 13:30-13:50 Transfusions: not a long-term alternative - *A. Hofmann*
- 13:55-14:20 Safety of EPOs in chemotherapy treated cancer patients: thrombosis and survival - *P. Gascon*
- 14:25-14:45 Break
- 14:50-15:10 The ESMO Anaemia Guideline - *M. Apro*
- 15:15-15:55 Integrating iron management as per guidelines - *Y. Beguin*
- 16:00-16:25 Panel discussion: addressing the treatment options with questions from the audience - *M. Apro*
- 16:30-17:00 **SESSION 2: Biosimilars**
- 16:30-16:55 Safety and efficacy of biosimilars in hemato-oncology - *M. Dicato*
- 17:00-18:00 **SESSION 3: Platelets or Thrombosis**  
Chairman: *M. Dicato*
- 17:00-17:20 New developments for thrombocytopenia management, ITP included - *C. Ay*
- 17:25-17:55 Thromboprophylaxis and treatment of DVT and PE in ambulatory cancer patients - *A. Falanga*

---

## Faculty

- |                       |                     |                             |
|-----------------------|---------------------|-----------------------------|
| Matti Apro - CH       | Anna Falanga - I    | Ruth Pettengell - UK        |
| Cihan Ay - A          | Pere Gascon - E     | Bernardo Leon Rapoport - ZA |
| Yves Beguin - B       | Axel Hofmann - CH   | Dirk Schrijvers - B         |
| Carsten Bokemeyer - D | Didier Kamioner - F | Reinhard Stauder - A        |
| Romano Danesi - I     | Hartmut Link - D    |                             |
| Mario Dicato - L      | Heinz Ludwig - A    |                             |

## Saturday, April 1<sup>st</sup>, 2017

- 08:30-10:30** SESSION 4: Neutropenia in Cancer Patients: a session in collaboration with MASCC  
Chairman: *C. Bokemeyer*
- 08:30-08:55 Growth factors in non chemotherapy related neutropenia - *H. Ludwig*
- 09:00-09:25 Development of evidence based guidelines for neutropenia prevention - *M. Aapro*
- 09:30-09:55 ESMO guidelines on neutropenia management - *B. Rapoport*
- 10:00-10:25 Is there a case for long-acting G-CSF? - *R. Danesi*
- 10:30-11:00** Break
- 11:00-11:50** SESSION 5: The elderly cancer patient: a session in collaboration with AFSOS  
Chairman: *M. Dicato*
- 11:00-11:20 Implications of anaemia and neutropenia in the elderly patients - *D. Kamioner*
- 11:25-11:45 EPO and thrombopoietic agents in MDS - *R. Stauder*
- 11:50-12:20** SESSION 6: Beyond solid tumours  
Chairman: *C. Bokemeyer*
- 11:50-12:15 Role of EPOs and G-CSF in lymphoma (Hodgkin's and non-Hodgkin's) - *R. Pettengell*
- 12:20-12:35** LEARNING ASSESSMENT (LA) FOR CME
- 12:40 CME certificates given only to those participants who have completed the LA
- 13:00-14:00** Buffet Lunch

---

## CME information

EACCME accreditation has granted 6 European CME credits (ECMEC).  
Italian accreditation has been requested.

Each participant will receive a certificate of attendance stating the relevant number of credits obtained during the conference.

The CME certificates can be granted only to the participants who have attended the entire conference.

The CME certificates will be distributed only at the end of the meeting.

## Topics covered during the course

- Supportive or palliative care: any difference?
- Consequences of anaemia
- Consequences of neutropenia
- Treatment of anaemia and neutropenia in cancer patients, including older patients
- An understanding of biosimilars in oncology
- Prevention and treatment of thrombosis in cancer patients
- Evaluation of risk factors for anaemia or neutropenia or thrombosis
- Transfusions: pros and cons
- Updated ESMO and other guidelines
- A perspective for older patients from AFSOS

## Objectives of the course

This course should clarify issues related to anaemia, neutropenia, thrombocytopenia and thrombosis in the cancer patient, including older patients, and the optimal way of preventing or treating these problems, including a review of guidelines. It will also focus on aspects still unresolved in the treatment of cancer treatment-associated anaemia like management of iron.

All aspects will be discussed with participation from the audience, also using case studies. At the end of the course the participants should be able to better prescribe preventative or corrective actions in these areas for cancer patients, including older patients, and critically follow the development of this important field in the near future.

## Course venue

Austria Trend Hotel Savoyen Vienna  
Rennweg 16 | A-1030 Wien

## Organising secretariat

Visionplus Srl  
Piazza San Pietro Martire, 6 | 20900 Monza (MB) | Italy  
Ph. +39 039 2326183 | Fax +39 039 3309918 | [medicaleducation@visionplus.it](mailto:medicaleducation@visionplus.it)

A course made possible thanks to



Financial support was provided by Pfizer Limited as a Medical and Educational Goods and Service.



**SANDOZ**

TEVA

Oncology

**AMGEN**